Steve Finkbeiner

Bio

Honors and Awards

Publications

• Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease. Finkbeiner S. Neurobiol Dis. 2020 12; 146:105088.
• Publisher Correction: Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Aron R, Pellegrini P, Green EW, Maddison DC, Opoku-Nsiah K, Oliveira AO, Wong JS, Daub AC, Giorgini F, Muchowski P, Finkbeiner S. Nat Commun. 2020 05 07; 11(1):2374.
• The Autophagy Lysosomal Pathway and Neurodegeneration. Finkbeiner S. Cold Spring Harb Perspect Biol. 2020 03 02; 12(3).
• Author Correction: Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Aron R, Pellegrini P, Green EW, Maddison DC, Opoku-Nsiah K, Osorio Oliveira A, Wong JS, Daub AC, Giorgini F, Muchowski P, Finkbeiner S. Nat Commun. 2020 Feb 21; 11(1):1065.
• Approaches to develop therapeutics to treat frontotemporal dementia. Elia LP, Reisine T, Alijagic A, Finkbeiner S. Neuropharmacology. 2020 04; 166:107948.
• Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD. Fang MY, Markmiller S, Vu AQ, Javaherian A, Dowdle WE, Jolivet P, Bushway PJ, Castello NA, Baral A, Chan MY, Linsley JW, Linsley D, Mercola M, Finkbeiner S, Lecuyer E, Lewcock JW, Yeo GW. Neuron. 2019 09 04; 103(5):802-819.e11.
• Cell death assays for neurodegenerative disease drug discovery. Linsley JW, Reisine T, Finkbeiner S. Expert Opin Drug Discov. 2019 09; 14(9):901-913.
• Automated four-dimensional long term imaging enables single cell tracking within organotypic brain slices to study neurodevelopment and degeneration. Linsley JW, Tripathi A, Epstein I, Schmunk G, Mount E, Campioni M, Oza V, Barch M, Javaherian A, Nowakowski TJ, Samsi S, Finkbeiner S. Commun Biol. 2019; 2:155.
• Genetic Regulation of Neuronal Progranulin Reveals a Critical Role for the Autophagy-Lysosome Pathway. Elia LP, Mason AR, Alijagic A, Finkbeiner S. J Neurosci. 2019 04 24; 39(17):3332-3344.
• The Cellular NMD Pathway Restricts Zika Virus Infection and Is Targeted by the Viral Capsid Protein. Fontaine KA, Leon KE, Khalid MM, Tomar S, Jimenez-Morales D, Dunlap M, Kaye JA, Shah PS, Finkbeiner S, Krogan NJ, Ott M. mBio. 2018 11 06; 9(6).
• Publisher Correction: Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Aron R, Pellegrini P, Green EW, Maddison DC, Opoku-Nsiah K, Wong JS, Daub AC, Giorgini F, Finkbeiner S. Nat Commun. 2018 10 15; 9(1):4333.
• Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Aron R, Pellegrini P, Green EW, Maddison DC, Opoku-Nsiah K, Oliveira AO, Wong JS, Daub AC, Giorgini F, Muchowski P, Finkbeiner S. Nat Commun. 2018 09 28; 9(1):3191.
• The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders. Willsey AJ, Morris MT, Wang S, Willsey HR, Sun N, Teerikorpi N, Baum TB, Cagney G, Bender KJ, Desai TA, Srivastava D, Davis GW, Doudna J, Chang E, Sohal V, Lowenstein DH, Li H, Agard D, Keiser MJ, Shoichet B, von Zastrow M, Mucke L, Finkbeiner S, Gan L, Sestan N, Ward ME, Huttenhain R, Nowakowski TJ, Bellen HJ, Frank LM, Khokha MK, Lifton RP, Kampmann M, Ideker T, State MW, Krogan NJ. Cell. 2018 07 26; 174(3):505-520.
• The Arc of cognition: Signaling cascades regulating Arc and implications for cognitive function and disease. Epstein I, Finkbeiner S. Semin Cell Dev Biol. 2018 05; 77:63-72.
• In Silico Labeling: Predicting Fluorescent Labels in Unlabeled Images. Christiansen EM, Yang SJ, Ando DM, Javaherian A, Skibinski G, Lipnick S, Mount E, O'Neil A, Shah K, Lee AK, Goyal P, Fedus W, Poplin R, Esteva A, Berndl M, Rubin LL, Nelson P, Finkbeiner S. Cell. 2018 04 19; 173(3):792-803.e19.
• Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L, Moreno CAM, Kamalakaran S, Goldstein DB, Gitler AD, Harris T, Myers RM, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE. Neuron. 2018 03 21; 97(6):1268-1283.e6.
• Assessing microscope image focus quality with deep learning. Yang SJ, Berndl M, Michael Ando D, Barch M, Narayanaswamy A, Christiansen E, Hoyer S, Roat C, Hung J, Rueden CT, Shankar A, Finkbeiner S, Nelson P. BMC Bioinformatics. 2018 03 15; 19(1):77.
• iPS cells in the study of PD molecular pathogenesis. Cobb MM, Ravisankar A, Skibinski G, Finkbeiner S. Cell Tissue Res. 2018 Jul; 373(1):61-77.
• Huntingtin Inclusions Trigger Cellular Quiescence, Deactivate Apoptosis, and Lead to Delayed Necrosis. Ramdzan YM, Trubetskov MM, Ormsby AR, Newcombe EA, Sui X, Tobin MJ, Bongiovanni MN, Gras SL, Dewson G, Miller JML, Finkbeiner S, Moily NS, Niclis J, Parish CL, Purcell AW, Baker MJ, Wilce JA, Waris S, Stojanovski D, Böcking T, Ang CS, Ascher DB, Reid GE, Hatters DM. Cell Rep. 2017 05 02; 19(5):919-927.
• Egocentric and allocentric visuospatial working memory in premotor Huntington's disease: A double dissociation with caudate and hippocampal volumes. Possin KL, Kim H, Geschwind MD, Moskowitz T, Johnson ET, Sha SJ, Apple A, Xu D, Miller BL, Finkbeiner S, Hess CP, Kramer JH. Neuropsychologia. 2017 Jul 01; 101:57-64.
• The Receptor-interacting Serine/Threonine Protein Kinase 1 (RIPK1) Regulates Progranulin Levels. Mason AR, Elia LP, Finkbeiner S. J Biol Chem. 2017 02 24; 292(8):3262-3272.
• Nrf2 mitigates LRRK2- and a-synuclein-induced neurodegeneration by modulating proteostasis. Skibinski G, Hwang V, Ando DM, Daub A, Lee AK, Ravisankar A, Modan S, Finucane MM, Shaby BA, Finkbeiner S. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1165-1170.
• Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntington's disease pathology. Mao Y, Chen X, Xu M, Fujita K, Motoki K, Sasabe T, Homma H, Murata M, Tagawa K, Tamura T, Kaye J, Finkbeiner S, Blandino G, Sudol M, Okazawa H. Hum Mol Genet. 2016 11 01; 25(21):4749-4770.
• Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System. Martinez FJ, Pratt GA, Van Nostrand EL, Batra R, Huelga SC, Kapeli K, Freese P, Chun SJ, Ling K, Gelboin-Burkhart C, Fijany L, Wang HC, Nussbacher JK, Broski SM, Kim HJ, Lardelli R, Sundararaman B, Donohue JP, Javaherian A, Lykke-Andersen J, Finkbeiner S, Bennett CF, Ares M, Burge CB, Taylor JP, Rigo F, Yeo GW. Neuron. 2016 Nov 23; 92(4):780-795.
• Identification of hepta-histidine as a candidate drug for Huntington's disease by in silico-in vitro- in vivo-integrated screens of chemical libraries. Imamura T, Fujita K, Tagawa K, Ikura T, Chen X, Homma H, Tamura T, Mao Y, Taniguchi JB, Motoki K, Nakabayashi M, Ito N, Yamada K, Tomii K, Okano H, Kaye J, Finkbeiner S, Okazawa H. Sci Rep. 2016 Sep 22; 6:33861.
• Serine 421 regulates mutant huntingtin toxicity and clearance in mice. Kratter IH, Zahed H, Lau A, Tsvetkov AS, Daub AC, Weiberth KF, Gu X, Saudou F, Humbert S, Yang XW, Osmand A, Steffan JS, Masliah E, Finkbeiner S. J Clin Invest. 2016 09 01; 126(9):3585-97.
• SPHK1/sphingosine kinase 1-mediated autophagy differs between neurons and SH-SY5Y neuroblastoma cells. Moruno Manchon JF, Uzor NE, Finkbeiner S, Tsvetkov AS. Autophagy. 2016 08 02; 12(8):1418-24.
• Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Zhang X, Abels ER, Redzic JS, Margulis J, Finkbeiner S, Breakefield XO. Cell Mol Neurobiol. 2016 Apr; 36(3):459-70.
• aB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease. Oliveira AO, Osmand A, Outeiro TF, Muchowski PJ, Finkbeiner S. Hum Mol Genet. 2016 05 01; 25(9):1677-89.
• A three-groups model for high-throughput survival screens. Shaby BA, Skibinski G, Ando M, LaDow ES, Finkbeiner S. Biometrics. 2016 09; 72(3):936-44.
• Cross-species translation of the Morris maze for Alzheimer's disease. Possin KL, Sanchez PE, Anderson-Bergman C, Fernandez R, Kerchner GA, Johnson ET, Davis A, Lo I, Bott NT, Kiely T, Fenesy MC, Miller BL, Kramer JH, Finkbeiner S. J Clin Invest. 2016 Feb; 126(2):779-83.
• Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouché M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Bütikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ceña V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et al. Autophagy. 2016; 12(1):1-222.
• Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases. Haston KM, Finkbeiner S. Annu Rev Pharmacol Toxicol. 2016; 56:489-510.
• Cytoplasmic sphingosine-1-phosphate pathway modulates neuronal autophagy. Moruno Manchon JF, Uzor NE, Dabaghian Y, Furr-Stimming EE, Finkbeiner S, Tsvetkov AS. Sci Rep. 2015 Oct 19; 5:15213.
• Sequence-Level Analysis of the Major European Huntington Disease Haplotype. Lee JM, Kim KH, Shin A, Chao MJ, Abu Elneel K, Gillis T, Mysore JS, Kaye JA, Zahed H, Kratter IH, Daub AC, Finkbeiner S, Li H, Roach JC, Goodman N, Hood L, Myers RH, MacDonald ME, Gusella JF. Am J Hum Genet. 2015 Sep 03; 97(3):435-44.
• Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Barmada SJ, Ju S, Arjun A, Batarse A, Archbold HC, Peisach D, Li X, Zhang Y, Tank EM, Qiu H, Huang EJ, Ringe D, Petsko GA, Finkbeiner S. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7821-6.
• Going retro: ancient viral origins of cognition. Campioni MR, Finkbeiner S. Neuron. 2015 Apr 22; 86(2):346-8.
• Cell-based screening: extracting meaning from complex data. Finkbeiner S, Frumkin M, Kassner PD. Neuron. 2015 Apr 08; 86(1):160-74.
• Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLoS One. 2014; 9(12):e91608.
• Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):16889-94.
• Targeting the low-hanging fruit of neurodegeneration. Neurology. 2014 Oct 14; 83(16):1470-3.
• Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Ann Neurol. 2014 Oct; 76(4):469-72.
• Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease. Front Cell Neurosci. 2014; 8:218.
• Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014 Aug; 10(8):677-85.
• Targeting the intrinsically disordered structural ensemble of a-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One. 2014; 9(2):e87133.
• ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest. 2014 Mar; 124(3):981-99.
• Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci. 2014 Jan 08; 34(2):418-33.
• Executive functions in premanifest Huntington's disease. Mov Disord. 2014 Mar; 29(3):405-9.
• Therapeutic modulation of eIF2a phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014 Feb; 46(2):152-60.
• PML in the Brain: From Development to Degeneration. Front Oncol. 2013 Sep 17; 3:242.
• Imaging-based chemical screening reveals activity-dependent neural differentiation of pluripotent stem cells. Elife. 2013 Sep 10; 2:e00508.
• Startups on the menu. Nat Biotechnol. 2013 Aug; 31(8):680.
• Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology. ACS Chem Biol. 2013 Sep 20; 8(9):1931-8.
• Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat Chem Biol. 2013 Sep; 9(9):586-92.
• Targeting H3K4 trimethylation in Huntington disease. Proc Natl Acad Sci U S A. 2013 Aug 06; 110(32):E3027-36.
• Arc in the nucleus regulates PML-dependent GluA1 transcription and homeostatic plasticity. Nat Neurosci. 2013 Jul; 16(7):874-83.
• Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Sci Transl Med. 2013 Jun 05; 5(188):188le2.
• NUB1 snubs huntingtin toxicity. Nat Neurosci. 2013 May; 16(5):523-5.
• Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease. FEBS Lett. 2013 Apr 17; 587(8):1139-46.
• Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci. 2013 Sep; 56:50-64.
• Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2013 Mar 19; 110(12):4697-702.
• Longitudinal imaging and analysis of neurons expressing polyglutamine-expanded proteins. Methods Mol Biol. 2013; 1017:1-20.
• Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet. 2012 Dec; 44(12):1302-9.
• Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012 Nov; 122(11):3955-9.
• Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One. 2012; 7(8):e43099.
• Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci. 2012 Aug 08; 32(32):11109-19.
• Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
• Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5803-8.
• Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem. 2012 May 04; 287(19):16017-28.
• Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure. J Mol Biol. 2012 Aug 24; 421(4-5):587-600.
• High-throughput screening in primary neurons. Methods Enzymol. 2012; 506:331-60.
• Protein aggregates in Huntington's disease. Exp Neurol. 2012 Nov; 238(1):1-11.
• A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy. 2011 Nov; 7(11):1273-94.
• Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol. 2011 Oct 30; 7(12):925-34.
• Arc in synaptic plasticity: from gene to behavior. Trends Neurosci. 2011 Nov; 34(11):591-8.
• Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine. Gittis AH, Hang GB, LaDow ES, Shoenfeld LR, Atallah BV, Finkbeiner S, Kreitzer AC. Neuron. 2011 Sep 08; 71(5):858-68.
• Drug discovery in Parkinson's disease-Update and developments in the use of cellular models. Int J High Throughput Screen. 2011 Jun; 2011(2):15-25.
• Huntington's Disease. Cold Spring Harb Perspect Biol. 2011 Jun 01; 3(6).
• Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, Edwards RH. J Biol Chem. 2011 Jun 10; 286(23):20710-26.
• A compact beta model of huntingtin toxicity. Zhang QC, Yeh TL, Leyva A, Frank LG, Miller J, Kim YE, Langen R, Finkbeiner S, Amzel ML, Ross CA, Poirier MA. J Biol Chem. 2011 Mar 11; 286(10):8188-96.
• Bringing SOD1 into the fold. Barmada S, Finkbeiner S. Nat Neurosci. 2010 Nov; 13(11):1303-4.
• Arc regulates spine morphology and maintains network stability in vivo. Peebles CL, Yoo J, Thwin MT, Palop JJ, Noebels JL, Finkbeiner S. Proc Natl Acad Sci U S A. 2010 Oct 19; 107(42):18173-8.
• PolyQ disease: too many Qs, too much function? Kratter IH, Finkbeiner S. Neuron. 2010 Sep 23; 67(6):897-9.
• Bridging the Valley of Death of therapeutics for neurodegeneration. Finkbeiner S. Nat Med. 2010 Nov; 16(11):1227-32.
• A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. Proc Natl Acad Sci U S A. 2010 Sep 28; 107(39):16982-7.
• Tau reduction prevents Abeta-induced defects in axonal transport. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Science. 2010 Oct 08; 330(6001):198.
• Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S. J Neurosci. 2010 Aug 04; 30(31):10541-50.
• Conformation sensors that distinguish monomeric proteins from oligomers in live cells. Ramdzan YM, Nisbet RM, Miller J, Finkbeiner S, Hill AF, Hatters DM. Chem Biol. 2010 Apr 23; 17(4):371-9.
• Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP. J Biol Chem. 2010 Mar 19; 285(12):8808-23.
• Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. J Neurosci. 2010 Jan 13; 30(2):639-49.
• Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP. Hum Mol Genet. 2010 Jan 01; 19(1):65-78.
• Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Barmada SJ, Finkbeiner S. Rev Neurosci. 2010; 21(4):251-72.
• Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. Neuron. 2009 Dec 24; 64(6):828-40.
• IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, Zeitlin SO, Finkbeiner S, Green KN, LaFerla FM, Bates G, Huang L, Patterson PH, Lo DC, Cuervo AM, Marsh JL, Steffan JS. J Cell Biol. 2009 Dec 28; 187(7):1083-99.
• High-content screening of primary neurons: ready for prime time. Daub A, Sharma P, Finkbeiner S. Curr Opin Neurobiol. 2009 Oct; 19(5):537-43.
• Protein turnover and inclusion body formation. Mitra S, Tsvetkov AS, Finkbeiner S. Autophagy. 2009 Oct; 5(7):1037-8.
• Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. Legleiter J, Lotz GP, Miller J, Ko J, Ng C, Williams GL, Finkbeiner S, Patterson PH, Muchowski PJ. J Biol Chem. 2009 Aug 07; 284(32):21647-58.
• Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, Merry DE. Hum Mol Genet. 2009 Jun 01; 18(11):1937-50.
• The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. Pintchovski SA, Peebles CL, Kim HJ, Verdin E, Finkbeiner S. J Neurosci. 2009 Feb 04; 29(5):1525-37.
• Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease. Mitra S, Tsvetkov AS, Finkbeiner S. J Biol Chem. 2009 Feb 13; 284(7):4398-403.
• The ubiquitin-proteasome pathway in Huntington's disease. Finkbeiner S, Mitra S. ScientificWorldJournal. 2008 Apr 20; 8:421-33.
• Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Neuron. 2007 Sep 06; 55(5):697-711.
• RNA decay back in play. Peebles CL, Finkbeiner S. Nat Neurosci. 2007 Sep; 10(9):1083-4.
• NMDA and AMPA receptors: old channels, new tricks. Rao VR, Finkbeiner S. Trends Neurosci. 2007 Jun; 30(6):284-91.
• Disease-modifying pathways in neurodegeneration. Finkbeiner S, Cuervo AM, Morimoto RI, Muchowski PJ. J Neurosci. 2006 Oct 11; 26(41):10349-57.
• Common threads in neurodegenerative disorders of aging. Beal MF, Bossy-Wetzel E, Finkbeiner S, Fiskum G, Giasson B, Johnson C, Khachaturian ZS, Lee VM, Nicholls D, Reddy H, Reynolds I, Teplow DB, Thal LJ, Trojanowski JQ, Walsh DM, Wetzel R, Wexler NS, Young AB, Bain L. Alzheimers Dement. 2006 Oct; 2(4):322-6.
• AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc. Rao VR, Pintchovski SA, Chin J, Peebles CL, Mitra S, Finkbeiner S. Nat Neurosci. 2006 Jul; 9(7):887-95.
• Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression. Bradley J, Carter SR, Rao VR, Wang J, Finkbeiner S. J Neurosci. 2006 Jan 25; 26(4):1065-76.
• Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches. Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, Weisgraber K, Finkbeiner S. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Dec 01; 61(Pt 12):1065-8.
• Automated microscope system for determining factors that predict neuronal fate. Arrasate M, Finkbeiner S. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3840-5.
• Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Nature. 2004 Oct 14; 431(7010):805-10.
• Using antibodies to analyze polyglutamine stretches. Brooks E, Arrasate M, Cheung K, Finkbeiner SM. Methods Mol Biol. 2004; 277:103-28.
• Secrets of a secretase: N-cadherin proteolysis regulates CBP function. Rao VR, Finkbeiner S. Cell. 2003 Sep 05; 114(5):533-5.
• An evaluation of specificity in activity-dependent gene expression in neurons. Bradley J, Finkbeiner S. Prog Neurobiol. 2002 Aug; 67(6):469-77.
• The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. Dev Cell. 2002 Jun; 2(6):831-7.
• New roles for introns: sites of combinatorial regulation of Ca2+- and cyclic AMP-dependent gene transcription. Finkbeiner S. Sci STKE. 2001 Aug 07; 2001(94):pe1.
• Calcium regulation of the brain-derived neurotrophic factor gene. Finkbeiner S. Cell Mol Life Sci. 2000 Mar; 57(3):394-401.
• CREB couples neurotrophin signals to survival messages. Finkbeiner S. Neuron. 2000 Jan; 25(1):11-4.
• Sending signals from the synapse to the nucleus: possible roles for CaMK, Ras/ERK, and SAPK pathways in the regulation of synaptic plasticity and neuronal growth. Curtis J, Finkbeiner S. J Neurosci Res. 1999 Oct 01; 58(1):88-95.
• Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Cell. 1998 Oct 02; 95(1):55-66.
• Ca2+ channel-regulated neuronal gene expression. Finkbeiner S, Greenberg ME. J Neurobiol. 1998 Oct; 37(1):171-89.
• To fear or not to fear: what was the question? A potential role for Ras-GRF in memory. Finkbeiner S, Dalva MB. Bioessays. 1998 Sep; 20(9):691-5.
• Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Neuron. 1998 Apr; 20(4):709-26.
• CREB: a major mediator of neuronal neurotrophin responses. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. Neuron. 1997 Nov; 19(5):1031-47.
• Spatial features of calcium-regulated gene expression. Finkbeiner S, Greenberg ME. Bioessays. 1997 Aug; 19(8):657-60.
• Ca(2+)-dependent routes to Ras: mechanisms for neuronal survival, differentiation, and plasticity? Finkbeiner S, Greenberg ME. Neuron. 1996 Feb; 16(2):233-6.
• Glial calcium. Finkbeiner SM. Glia. 1993 Oct; 9(2):83-104.
• Calcium excitability and oscillations in suprachiasmatic nucleus neurons and glia in vitro. van den Pol AN, Finkbeiner SM, Cornell-Bell AH. J Neurosci. 1992 Jul; 12(7):2648-64.
• Calcium waves in astrocytes-filling in the gaps. Finkbeiner S. Neuron. 1992 Jun; 8(6):1101-8.
• Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect. Renzi R, Finkbeiner S. Am J Emerg Med. 1991 Nov; 9(6):551-2.
• Endothelin induces a sustained rise in intracellular calcium in hippocampal astrocytes. Goldman RS, Finkbeiner SM, Smith SJ. Neurosci Lett. 1991 Feb 11; 123(1):4-8.
• Ca2+ waves in astrocytes. Cornell-Bell AH, Finkbeiner SM. Cell Calcium. 1991 Feb-Mar; 12(2-3):185-204.
• Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ. Science. 1990 Jan 26; 247(4941):470-3.
• Synthesis and characterization of a series of diarylguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties. Keana JF, McBurney RN, Scherz MW, Fischer JB, Hamilton PN, Smith SM, Server AC, Finkbeiner S, Stevens CF, Jahr C. Proc Natl Acad Sci U S A. 1989 Jul; 86(14):5631-5.
• Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure. Goldman RS, Finkbeiner SM. N Engl J Med. 1988 Nov 03; 319(18):1224-5.
• Applications of quantitative measurements for assessing glutamate neurotoxicity. Finkbeiner S, Stevens CF. Proc Natl Acad Sci U S A. 1988 Jun; 85(11):4071-4.

More Publications

Contact